These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 620500

  • 1. Intensive iron-chelation therapy with desferrioxamine in iron-loading anaemias.
    Pippard MJ, Callender ST, Weatherall DJ.
    Clin Sci Mol Med; 1978 Jan; 54(1):99-106. PubMed ID: 620500
    [Abstract] [Full Text] [Related]

  • 2. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
    Hussain MA, Green N, Flynn DM, Hoffbrand AV.
    Lancet; 1977 May 07; 1(8019):977-9. PubMed ID: 67469
    [Abstract] [Full Text] [Related]

  • 3. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A, Schwartz E.
    J Pediatr; 1978 Apr 07; 92(4):643-7. PubMed ID: 633031
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L.
    Br Med J (Clin Res Ed); 1987 Dec 12; 295(6612):1509-12. PubMed ID: 3122880
    [Abstract] [Full Text] [Related]

  • 6. Iron absorption in iron-loading anaemias: Effect of subcutaneous desferrioxamine infusions.
    Pippard MJ, Callender ST, Warner GT, Weatherall DJ.
    Lancet; 1977 Oct 08; 2(8041):737-9. PubMed ID: 71542
    [Abstract] [Full Text] [Related]

  • 7. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD, Shurin SB, Nathan DG.
    N Engl J Med; 1976 Jun 24; 294(26):1421-3. PubMed ID: 1272274
    [Abstract] [Full Text] [Related]

  • 8. Prevention of iron loading in transfusion-dependent thalassaemia.
    Pippard MJ, Letsky EA, Callender ST, Weatherall DJ.
    Lancet; 1978 Jun 03; 1(8075):1178-81. PubMed ID: 77945
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR, Mahony BS, Githens JH, Rhoades ED.
    Am J Pediatr Hematol Oncol; 1982 Jun 03; 4(2):115-23. PubMed ID: 7114394
    [Abstract] [Full Text] [Related]

  • 13. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
    Boturao-Neto E, Marcopito LF, Zago MA.
    Braz J Med Biol Res; 2002 Nov 03; 35(11):1319-28. PubMed ID: 12426631
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C, Franchini M, Gandini G, Vassanelli A, De Gironcoli M, Aprili G.
    Haematologica; 1998 Sep 03; 83(9):788-90. PubMed ID: 9825575
    [Abstract] [Full Text] [Related]

  • 16. Continuous subcutaneous administration of deferoxamine in patients with iron overload.
    Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, Rosenthal A, Nathan DG.
    N Engl J Med; 1977 Aug 25; 297(8):418-23. PubMed ID: 882111
    [Abstract] [Full Text] [Related]

  • 17. Desferrioxamine-induced iron excretion in humans.
    Pippard MJ.
    Baillieres Clin Haematol; 1989 Apr 25; 2(2):323-43. PubMed ID: 2660931
    [Abstract] [Full Text] [Related]

  • 18. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004 Apr 25; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 19. Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children.
    Llados i Vallory EA, Girot R, Lenoir G, Payet M, Houze P, Bourdon R.
    Eur J Pediatr; 1989 Apr 25; 148(6):503-6. PubMed ID: 2744011
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.